【US Stock Market Movement】Grail surges on September 24: FDA support and early screening with Galleri
Bitget异动解读2026/09/24 14:00Grail September 24 Surge Analysis
Keywords: FDA support, Galleri early screening
1. On September 23, 2026, the Medical Devices Advisory Committee of the US FDA determined by a vote of 7 to 2 that the benefits of GRAIL's Galleri multi-cancer early detection product outweigh the risks; safety received 10 out of 10 support, and efficacy received 6 out of 4 support.
2. On September 23, 2026, GRAIL's Galleri, by using AI to analyze cfDNA methylation patterns in blood, can screen for more than 50 types of cancer, with a specificity as high as 99.85% and a positive predictive value of about 77%. The product's regulatory review has made key progress.
(Disclaimer: This content is summarized from publicly available information using AI technology and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nymex US crude oil futures main contract dropped 1% intraday to $93.66 per barrel.
Spot gold breaks through $4280/ounce, up 0.15% intraday
Anthropic and Akamai sign a $11.6 billions computing power agreement, marking the largest contract in Akamai's history
Anthropic has signed a seven-year, $11.6 billion computing power contract with Akamai, marking the largest order in Akamai's history. Akamai will provide CPU computing power, with related capital expenditures expected to be approximately $5.5 billion. Revenue from this business is projected to reach $150 million to $300 million next year. As a significant part of the transaction, Akamai issued warrants to Anthropic, allowing it to purchase Series B shares that can be converted into common stock.
Oracle commits to bearing the risk of power delivery for the new Mexico data center
Crypto prices
More
